Liraglutide
Approvedaka Saxenda, Victoza
The original once-daily GLP-1. Semaglutide's older, shorter-acting predecessor.
Mechanism
A GLP-1 agonist you inject daily instead of weekly. Same idea as semaglutide, slows the stomach and raises satiety, just an older and shorter-acting molecule. It was the first GLP-1 to get the green light for chronic weight management.
Regulatory & Safety Status
Approved: Victoza for diabetes, Saxenda for obesity. Prescription drug, mostly superseded by the weekly options now.
Research
Combined empagliflozin and liraglutide therapy protects against tacrolimus-induced pancreatic and renal injury associated with oxidative stress reduction
A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease
Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome
Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy
Latest liraglutide research